Botanix Pharmaceuticals (ASX:BOT) – Jumps 5 Per Cent on a Single Tick, Not a Biotech Revival

Aditi Sarkar

03 August 2026 03:04 PM AEST

Botanix Pharmaceuticals (ASX:BOT) – Jumps 5 Per Cent on a Single Tick, Not a Biotech Revival

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

That price looks jarring, given Botanix placed AUD 70 million of stock at 30 cents in June 2024, the week its lead product won US approval.
ASX tick sizes drop to a tenth of a cent below 10 cents, so a rise from 1.9 cents to 2.0 cents is one tick.
By 11.30am fewer than 1.9 million shares had traded, worth under AUD 40,000.
The S&P/ASX 200 health care index was down 0.37 per cent at the same time, among the market's weaker parts, while the benchmark sat at 8,953.80, off 0.26 per cent.

A 5 per cent move worth a tenth of a cent That price looks jarring, given Botanix placed AUD 70 million of stock at 30 cents in June 2024, the week its lead product won US approval. Google Finance, TradingView and Botanix's own readers page all showed the same figures on Monday morning.

Company Overview

That price looks jarring, given Botanix placed AUD 70 million of stock at 30 cents in June 2024, the week its lead product won US approval. Google Finance, TradingView and Botanix's own readers page all showed the same figures on Monday morning.

Latest Update

The move is the smallest the stock can make. ASX tick sizes drop to a tenth of a cent below 10 cents, so a rise from 1.9 cents to 2.0 cents is one tick. Arithmetically that is 5.26 per cent. Commercially it is close to nothing. By 11.30am fewer than 1.9 million shares had traded, worth under AUD 40,000. Market Capitalisation is roughly AUD 52 million. Nor was there a sector wave behind it.

Operations and Strategic Direction

Sofdra (sofpironium) topical gel was approved by the US Food and Drug Administration in June 2024 for primary axillary hyperhidrosis, or excessive underarm sweating, in patients aged nine and over. It was the first new chemical entity approved for the condition, which Botanix says affects roughly 10 million Americans. The US launch came in February 2025. The June 2026 quarter was the strongest yet on Volume .

Financial and Market Snapshot

The gap between those headlines and the money reaching Botanix is the central fact here. Net Revenue for the quarter was AUD 10.1 million, up 45 per cent from AUD 6.9 million, and AUD 33.2 million over 12 months. The gross-to-net Yield , the share of list-price sales retained after rebates, discounts, patient assistance and pharmacy fees, improved to 22 per cent from 18 per cent as US patients cleared the January insurance deductible reset. Why the cash line matters most

Broader Context

The next update should clarify whether current developments are translating into measurable progress. Market expectations can change quickly when operational results differ from earlier assumptions. Cash conversion offers another practical measure of the quality of reported Earnings .

What May Be Watched Next

FY26 results are due late August. The September-quarter 4C will show whether the 12 per cent cost reduction holds and gross-to-net yield climbs past 22 per cent. Watch cash at quarter end against the 4.82-quarter estimate, any movement on the Kreos Facility , and any outcome from the licensing discussions management has flagged.

Key Risks

The company remains loss-making, and the June quarter's low burn was partly a deferral. Any deterioration in the runway, or an inability to draw the remaining Kreos Tranche , raises the prospect of further dilution on an already expanded register, and secured Debt ranks ahead of Equity . Reimbursement is the swing Factor : with 22 cents in the dollar converting to revenue, payer decisions can matter more than prescription growth.

FAQs

Q: What is the main focus of Botanix Pharmaceuticals?

A:That price looks jarring, given Botanix placed AUD 70 million of stock at 30 cents in June 2024, the week its lead product won US approval.

Q: What was the latest update involving Botanix Pharmaceuticals?

A:The move is the smallest the stock can make. ASX tick sizes drop to a tenth of a cent below 10 cents, so a rise from 1.9 cents to 2.0 cents is one tick.

Q: What numerical detail stands out for Botanix Pharmaceuticals?

A:ASX tick sizes drop to a tenth of a cent below 10 cents, so a rise from 1.9 cents to 2.0 cents is one tick.

Q: What may be watched next for Botanix Pharmaceuticals?

A:FY26 results are due late August. The September-quarter 4C will show whether the 12 per cent cost reduction holds and gross-to-net yield climbs past 22 per cent.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.